Stock Price & Analysis

Based on the recent data and market analysis, here's a concise assessment of THC stock:

Technical Analysis The stock shows a strong upward momentum with the price currently at $130.11 in post-market trading. The stock has formed higher lows and higher highs over the past month, indicating a bullish trend. The RSI-14 at 41.82 suggests the stock is neither overbought nor oversold, providing room for further upside.

Fundamental Strength Recent analyst coverage remains highly positive. Barclays maintains a Buy rating with a price target of $161.00, while the overall analyst consensus suggests a Strong Buy with an average price target of $174.63, representing a potential 34% upside from current levels. The company's P/E ratio of 4.44 indicates the stock is trading at an attractive valuation compared to industry peers.

Recent Developments The company has demonstrated strong execution with recent strategic divestitures and positive earnings performance. The sale of three hospitals to Novant Health is expected to improve financial flexibility and enhance operational efficiency.

Based on the technical momentum and strong fundamental backdrop, THC stock appears to be a buy at current levels. The stock has shown resilience in recent trading sessions and maintains strong institutional support.

Based on the provided data and recent analyst reports, here's a concise price prediction for THC stock in 2025:

THC is expected to reach $174-185 by end of 2025, representing a ~35-40% upside from current levels. This projection is supported by:

Strong analyst consensus with recent price targets from Barclays ($161) and KeyBanc ($185), indicating a "Strong Buy" rating with average target of $174.63. The company's solid fundamentals, including P/E ratio of 4.44 and strong earnings performance, support this bullish outlook.

Technical analysis shows THC trading above key moving averages with strong momentum, suggesting continued upward trend potential through 2025.

The S1 support level for THC Stock is $126.18 ,The R1 resistant level for THC Stock is $140.3.

As of the end of day on 2025-02-27, the price of THC Stock was $130.36.

The target price for THC Stock according to analyst rating is 171.91, with the highest price target at 195.00 and the lowest at 140.00. Analysts have a Strong Buy rating on THC Stock overall.

The market cap of THC is $12.5B.

Based on the provided data, here's a concise analysis of THC's valuation:

THC is currently trading at reasonable valuation levels. The company's forward P/E ratio of 12.96 and EV/EBITDA of 6.9 are below industry averages, suggesting the stock is not overvalued.

Key Positive Factors:

• Net income increased significantly from $411M in 2022 to $611M in 2023
• ROE improved from 37.79% to 44.44% year-over-year
• Current ratio strengthened from 1.34 to 1.51
• Debt-to-equity ratio decreased from 613.22% to 481.30%, showing improved leverage

Recent Performance:

• Stock is trading at $130.11 in post-market, down 1.10% from regular session close
• RSI-14 at 41.82 indicates neutral momentum
• Trading below its 200-day SMA of $144.04, suggesting some technical weakness

Analyst Consensus: The stock has strong analyst support with an average price target of $184.56, representing significant upside potential from current levels. Barclays maintains a Buy rating with a $161 price target.

Based on the fundamental improvements, reasonable valuation metrics, and strong analyst support, THC appears fairly valued to slightly undervalued at current levels. The company's improved operational efficiency and debt reduction efforts provide a solid foundation for future growth.

Tenet Healthcare Corporation is a diversified healthcare services company. The Company’s care delivery network includes USPI Holding Company, Inc. (USPI), which operates or has ownership interests in ambulatory surgery centers and surgical hospitals. The Company also operates acute care and specialty hospitals, as well as other outpatient facilities, including surgical hospitals, and ambulatory surgery centers (ASC), among others. The Company operates through two segments: Hospital Operations and Services, and Ambulatory Care. The Hospital Operations and Services segment, which is comprised of acute care and specialty hospitals, a network of employed physicians and ancillary outpatient facilities, as well as the revenue cycle management and value-based care services that the Company provide to hospitals, health systems, physician practices, employers, and other clients. The Ambulatory Care segment, which is comprised of USPI’s ASCs and surgical hospitals.

Based on the provided data and analysis, here's a concise 3-sentence price prediction for THC stock by 2030:

Tenet Healthcare (THC) is projected to reach approximately $225-240 by 2030, driven by its strategic hospital portfolio optimization, continued USPI segment expansion, and improving operational efficiencies as evidenced by recent analyst reports. The growth trajectory is supported by multiple analyst upgrades with current price targets ranging from $161-217, suggesting strong near-term momentum that could compound over the 5-year period. However, this projection assumes successful execution of the company's strategic initiatives including the recently announced South Carolina hospital divestitures and continued market share gains in the ambulatory surgery center space, while factoring in potential healthcare policy changes under future administrations.

THC has a total of 78144 employees.